Tirofiban Combination Therapy for Acute Ischemic Stroke: A Systematic Review and Meta‐Analysis [PDF]
Brain and BehaviorIntroduction Acute ischemic stroke (AIS) is a leading cause of morbidity and mortality globally. Standard antiplatelet therapies, while partially effective, do not fully inhibit all pathways of platelet aggregation, leaving patients at risk of recurrent ...
Abdullah Bin Kamran +9 more
doaj +3 more sources
Local tirofiban infusion for remnant stenosis in large vessel occlusion: tirofiban ASSIST study [PDF]
BMC Neurology, 2020 Background Compared with embolic occlusions, intracranial atherosclerotic stenosis (ICAS)-related large vessel occlusions (LVOs) often require rescue treatment following mechanical thrombectomy (MT).
Yong-Won Kim +11 more
doaj +4 more sources
Effects of tirofiban on haemostatic activation in vitro [PDF]
British Journal of Anaesthesia, 2004 Thrombin plays a critical role in normal haemostasis and pathological thrombosis. Heparin has long been a mainstay choice of antithrombotic regimen in cardiac patients, but persistent thrombin generation seems to occur during heparin therapy. Because platelets are integral to primary haemostasis and clot formation, we evaluated the use of tirofiban ...
Kenichi A. Tanaka +5 more
openalex +4 more sources
Tirofiban-induced acute profound thrombocytopenia in endovascular therapy for acute ischemic stroke: a rare case report [PDF]
BMC NeurologyBackground Studies have shown that tirofiban (a glycoprotein IIb/IIIa receptor antagonist) is effective in the endovascular treatment of cerebrovascular diseases. However, it has also been reported that tirofiban can cause thrombocytopenia.
Jiuling Liu +4 more
doaj +2 more sources
Effect of Intravenous Tirofiban Versus Placebo on Excellent Outcome in Patients With Acute Ischemic Stroke: The Multicenter, Randomized INSTANT Trial Protocol [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground It is common that symptoms do not improve or even worsen after intravenous thrombolysis (IVT) in acute ischemic stroke. However, it remains unknown whether early administration of tirofiban after IVT may improve clinical outcomes.
Fan Zhang +25 more
doaj +2 more sources
Safety of Tirofiban in Acute Ischemic Stroke [PDF]
Stroke, 2011 Background and Purpose— Tirofiban is a highly selective, fast-acting nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist with a short half-life time. Glycoprotein IIb/IIIa antagonists are effective for the treatment of acute coronary syndromes proven in large clinical trials.
Otto W Witte, Arno Villringer
exaly +5 more sources
Tirofiban-Induced Profound Thrombocytopenia: A Case Report. [PDF]
CureusPlatelet glycoprotein IIB/IIIA antagonists are potent inhibitors of platelet aggregation. Although the incidence of thrombocytopenia following their administration is relatively low, it can sometimes lead to fatal consequences. We report a case of a 57-year-old gentleman presenting with non-ST elevation myocardial infarction complicated with tirofiban ...
Al Achkar Z +3 more
europepmc +3 more sources
Comparison of Early Invasive and Conservative Strategies in Patients with Unstable Coronary Syndromes Treated with the Glycoprotein IIb/IIIa Inhibitor Tirofiban [PDF]
New England Journal of Medicine, 2001 Christopher P Cannon +2 more
exaly +2 more sources
Safety of tirofiban and dual antiplatelet therapy in treating intracranial aneurysms
Stroke and Vascular Neurology, 2019 Background Endovascular treatment of intracranial aneurysms usually involves stent-assisted coiling (SAC) and flow diverters. Glycoprotein IIb/IIIa inhibitors such as tirofiban and dual antiplatelet therapy (DAPT) are required to prevent thromboembolic ...
Edgar A Samaniego +2 more
exaly +3 more sources
Therapeutic efficiency of tirofiban in acute coronary syndromes [PDF]
The Lancet, 2000 John R. Burnett +4 more
+9 more sources